Bizarre IPO Cancelled Due to Shareholder Failure to Perform

Vascular Biogenics issued shares in its $65 million IPO last week but after 6 days of trading on the Nasdaq, the company cancelled the offering and all trades were reversed.

This bizarre situation resulted from the refusal of a standby purchaser, its largest shareholder, to purchase up to $30 million of the offering. When other buyers refused to fill the hole, the underwriters had no choice but to cancel the deal.

The purchaser, a former Goldman Sachs banker, apparently thought that the offering would receive greater public buy in, reducing his obligation. The underwriters believed that they could cancel the offering as it hadn’t settled by the time they pulled the plug.

Vascular Biogenics, like many biotechs, hasn’t made a profit in 14 years and has a $100 million stockholders’ deficit.

About JeffKoeppel

I am a corporate/securities attorney in the Washington, DC area. Prior to joining the firm, I was a Senior Attorney Advisor in the Division of Corporation Finance at the U.S. Securities and Exchange Commission. I am a member of the Bars of the States of Maryland, New York and the District of Columbia. You can also follow this blog on LinkedIn at:
This entry was posted in Banking, Broker dealers, Congress, Crowd Fund Act, Crowd Fund Act of 2012, Crowd Funding At the Margins, Crowd Funding Platforms, FINRA, Funding Portals, Investments, Jobs, Legislative Intent, SEC, Wall Street and tagged , , , , , , , , , , , , , , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.